“Rates of life-threatening bleeding in U.S. infants have risen sharply since 2017 as parents increasingly refuse protective newborn doses of vitamin K, a trend that coincides with a growing wave of mistrust toward vaccines and other newborn interventions, two studies published on Thursday found…Woolf and colleagues studied medical records from 11 million infants six months and younger between 2017 and 2025. During that time, the percentage of newborns who received a vitamin K shot fell from 97.7% to 95%, while the rate of vitamin K deficiency bleeding nearly quadrupled and appeared to be accelerating. Of more than 11 million births, there were a total of 5,217 bleeding events over that multi-year period…
An exclusive analysis for Reuters of more than 1 million births nationwide by health data and analytics company Truveta found the percentage of vitamin K refusals accelerated sharply in the first half of 2026, jumping by more than 57% from January through June.”
Methods: Researchers evaluated prospectively collected data from 1,007 children enrolled in the INternational Study Group of Pediatric Pancreatitis: In search for a cuRE (INSPPIRE-2) consortium. Fecal elastase (FE) performance was assessed against individual markers of fat malabsorption and a composite reference standard in which the presence of any 1 of the following was considered consistent with fat malabsorption in lieu of a gold-standard pancreas function test: (1) clinical diagnosis of exocrine pancreatitic insufficiency (EPI), (2) vitamin A or E deficiency***, or (3) body mass index z-score £–2. ***The authors note that vitamin levels were only available for 1/5 of the cohort.
Key findings:
EPI was diagnosed in 195/1007 (19.4%) children with ARP/CP. The 7-year cumulative incidence of EPI after the first pancreatitis episode was 24%. Genetic risk factors were associated with earlier progression to EPI (hazard ratio 1.56
Sensitivity and Specificity for fecal elastase showed a sensitivity of 55.8% and a specificity of 82.8% at a cut-off of 100 µg/g stool. At a cut-off of 200 µg/g stool, sensitivity was 65.1% and specificity was 75.5%.
Negative predictive value for fecal elastase was 92% and 93% at cut-offs of 100 μg/g and 200 μg/g stool, respectively
Kaplan-Meier plot showing cumulative incidence of exocrine pancreatic insufficiency (EPI) over timeKaplan-Meier plot for time to exocrine pancreatic insufficiency (EPI) stratified by genetic risk factor.
Discussion Points:
Fecal elastase “has drawbacks of giving false positive results in a liquid stool sample and is reliably diagnostic only of severe EPI.”
“A cut-off of 132 μg/g stool (sensitivity-63%, specificity-81%, Youden index-0.44) showed the best trade-off between sensitivity and specificity.”
“Approximately one-fifth of children with EPI were receiving PERT prior to EPI diagnosis, which may have attenuated manifestations such as growth failure or fat-soluble vitamin deficiencies [and]…reduce the sensitivity results for FE.”
The “majority of patients in our cohort had only a single FE test reported, suggesting a potential underestimation of evolving or progressive EPI.”
My take: With its high negative predictive value, fecal elastase remains a very good screening test for EPI. Serial assessments are needed in patients with ARP and CP due to the high frequency of EPI in these patients; as such, the authors suggest yearly evaluation in most of these patients.
Background: Gastroparesis is a difficult condition to treat and medical options are limited.
Study population: In total, 577 patients with gastroparesis (GP) who underwent pyloric dilatation (PyD) were studied with age range from 2 years to 51 years. 5 of the 12 selected studies enrolled children.
Methods: Various pyloric dilators (PyD) were used: hydraulic dilation with controlled radial expansion (CRE) balloon was most common [5] followed by pneumatic [3], and EsoFLIP [1]. In children, the size of CRE balloon was based on age or weight, but the cutoffs employed were variable. In adults, the CRE balloon diameter most often used was 20 mm.
Key findings:
Quality of studies was fair to poor.
Symptom improvement with PyD was described in 37%–85% of treated patients. PyD plus botulin toxin efficacy was reported as 50%–80%.
Benefits were reported as early as 2 weeks and up to 2 years after intervention.
None of the studies reported complications with PyD. One study reported transient post procedural pain in 60% of patients after PyD for a median of 1 day.
Discussion points:
“Santucci et al. [24] is the only study with a placebo-controlled arm in this review, underscoring the need for more rigorous trials to decide on PyD’s role (with or without botox) in GP.” In this pediatric study, 76% of cases showed partial or complete improvement compared with 49% controls within 12 months (P = 0.004). Younger children tended to respond more favorably to the procedure (P = 0.08).
Some of the problems with GP are the variable methodology in establishing a diagnosis and the lack of validated markers for pyloric function.
Response to dilatation may indicate a higher likelihood of responding to more invasive treatment.
“With PyD alone, response rates were higher in children (71%–95%) than adults (27%–53%) with CRE balloon.”
My take (borrowed in part from the authors): “Symptom improvements presented across multiple studies should be interpreted with caution given the lack of controlled data and risk of bias… However, robust randomized placebo-controlled trials are essential to determining the true efficacy of pyloric dilation in gastroparesis.” The higher reported response rates in children could be related to higher rates of more transient disorders.
Methods: In this retrospective registry-based nationwide study from Finland, all pediatric short bowel–associated intestinal failure (IF) patients (n=20) who were treated with teduglutide were reviewed. Median follow-up was 31 months.
Key findings:
The Good:
In the 19 who received treatment for 6 months, the median reductions in daily parenteral support (PS) energy and fluid volume requirement were 42% and 28 mL/kg/day, respectively.
Weekly infusion-free nights increased from 0.5 to 4.
Six patients (32%) successfully weaned off PS (while on teduglutide). Three patients who weaned off PS were subsequently able to come off teduglutide. Their pretreatment PS energy provision ranged from 19% to 33%, and all retained some colon (30%–100%). All of these patients who were able to stop teduglutide had received treatment for a minimum of 23 months.
The Bad:
Four patients (20%) experienced intestinal bleeding while on teduglutide. This occurred on average 5 months (range: 3–8) after treatment initiation.
Stomal prolapses occurred in all patients with end-jejunostomies.
Patients in our study had endoscopies performed every 12–24 months, and none had mucosal neoplastic lesions. However, inflammatory changes were common.
Periodic withdrawal (n = 37) led to adverse effects on 84% of occasions (n = 32). Serious adverse effects included unplanned hospitalizations (n=2), dehydration in 19 (51%), and diarrhea in 28 (76%) occasions. There was also suspected D-lactic acidosis, significant electrolyte or blood glucose disturbances, and weight loss. One patient was treated in the intensive care unit due to severe electrolyte disturbances. To mitigate these adverse effects, their clinicians increased intravenous fluid volume or parenteral energy during 15 withdrawal periods. Another 15 periods were terminated prematurely due to deteriorating clinical condition, including weight loss (n = 4), dehydration (n = 9), acidosis (n = 8), diarrhea (n = 3), or combinations of these.
Discussion:
“Mandatory drug-free withdrawal periods due to the national reimbursement policy caused frequent adverse effects.” Finnish policy requires yearly 4-week teduglutide-free periods to renew reimbursement. “Hospital visits took place in 38% of the withdrawal periods, and two children were hospitalized.”
“SBS patients with remaining colon have better chances of weaning off PS…The patients who weaned off both teduglutide and PS had low PS energy requirements at the start of the study and may have been able to wean off even without the medication.”
My take: For most SBS patients, I would not recommend teduglutide. This study shows the frequent adverse consequences during the study period; more adverse effects are possible years later, which is why endoscopic surveillance is recommended in those who have received teduglutide. In addition, there is a high risk of severe adverse effects if the medication is stopped, whether planned or unplanned. In addition to the downsides apparent in this study, the authors neglect to explore the financial costs of teduglutide therapy, including the indirect costs related to endoscopic monitoring and complications.
Methods: The authors randomized 132 infants (infusion, n = 68; bolus, n = 64). The median gestational age and birth weight were 26.4 ± 1.2 weeks and 752 ± 140 g. Bolus feedings were provided every 2 hours through an orogastric tube over a duration of 10-20 minutes by gravity. Drip feeds: over a 24-hour time period, milk was delivered in 4 infusion cycles. Each infusion cycle comprised of 5 hours of continuous milk infusion followed by an hour of feeding break.
Key findings:
The median time to full enteral feedings was similar: infusion: 10 days [IQR: 7-12]; bolus: 9 days [IQR: 7-12], P = .82
The mean (SD) rate of weight gain at discharge was similar: infusion 15.3 ± 2.6 g/kg/day vs bolus 15.7 ± 2.8 g/kg/day
The infusion group had significantly fewer days of feeding interruptions (6.7 days [5.6-8.1] vs 8.7 [7.4-10.1] per 100 patient days, P = .03) in the first 28 days
Duration of hospitalization and morbidities were similar in study groups
Kaplan-Meier curves for time to full enteral feeds in both groups. The dashed line represents the median time to full enteral feeds in both groups (10 days).
Discussion Points:
“Feeding intervals may play an important role in nutrient absorption and assimilation in neonates. An in vitro model of simulated feeding of thawed unprocessed donor human milk indicated that continuous feeding resulted in 40%, 35%, and 20% losses of fat, calcium, and phosphorus content, respectively, compared with 6%, 9%, and 7% losses of the same macronutrients when bolus fed. Periodic manual agitation of infusion pumps, use of inverted or vertically oriented infusion systems, and infusion rates of 5 mL/hour have been identified as important approaches (level II evidence) to combat fat losses from milk infusions”
There were feeding interruptions in this study. “In our study, consistent with current feeding practices, infants were exclusively human milk fed until 33 weeks of gestation and feeding decisions were not affected by gastric residual volumes.”
My take (borrowed from the authors): “Extended infusion feedings were noninferior to intermittent bolus feedings for hospital weight gain in infants born with ELBW.”
MT Barakat et al. J Pediatr 2026;298:115248.The Environmental Impact of Pediatric Endoscopy: Small Feet Have a Disproportionately Large Carbon Footprint
Methods: The authors evaluated the carbon footprint of a pediatric endoscopy unit through a 2-week audit.
Key Findings:
Pediatric procedures generated 3.48 kg waste per case with an annualized carbon footprint of 108.32 metric tons.
Mean Disposable Waste Per CaseSources of annual 108.32 metric tons of CO2 generated annually by a single pediatric endoscopy center. (likely an underestimate)
Discussion:
In comparison to an adult study, CO2 generation was “approximately 2.5 times higher than the CO2 produced by roughly the same number of adult endoscopy procedures.”
“Several factors may contribute to this heightened carbon footprint… Perhaps the most significant is the performance of pediatric endoscopy procedures in the operating room rather than in independent free-standing endoscopy units at our center and many other centers…cleaning guidelines in the operating room environment tend to be more energy-intensive.”
“The carbon footprint we calculated does not include the distance traveled to obtain care at our institution.”
“ERCP produced the most solid waste of all procedures performed, which is not surprising given the abundance of single-use devices.”
“Estimates based on adult endoscopy suggest that up to 40% of endoscopy-associated waste could be diverted from landfills through recycling or reprocessing initiatives…In addition, we noted overuse of hazardous waste disposal, which requires incineration and produces harmful toxins and greenhouse gases.”
My take: This is a useful study showing the substantial carbon footprint and waste of pediatric endoscopy procedures, especially in hospital settings. I disagree with one part of the authors’ discussion:
“Avoidance of unnecessary procedures is the best way to minimize the endoscopy carbon footprint. However, case selection within pediatrics is a careful process, and thus, avoidable procedures are generally not performed.“
In my view, there is high variability in the use of endoscopy based on practitioner’s clinical care; there are many low yield cases with trivial findings. In addition, beyond a practitioners’ judgement and integrity, there are not incentives for careful patient selection.
Personal-cleansing brand Dude Wipes announced Thursday its new line of flushable khakis. “Every guy knows what it’s like to walk around with a load in his slacks, but you don’t have to anymore with these stylish pants you can just tear off and drop in the toilet,” said CEO Sean Riley, adding that the slim-fit chinos were made with a unique sewer- and septic-safe fabric, and came in a variety of manly scents for extra freshness not to be found in traditional khakis, which simply absorb fecal odor.
Background: “Generally, patients with normal or mildly elevated ALT levels have a low risk of disease progression and HCC, and regular follow-up instead of immediate antiviral therapy is recommended in most international CHB guidelines.3–6 However, emerging evidence suggests that a considerable proportion of patients with CHB and normal or mildly elevated ALT levels have significant histological changes and relatively high risk of HCC and cirrhosis, especially in individuals with high HBV DNA levels.7–13 The interim results from a recent randomized controlled trial (ATTENTION) add important evidence that early antiviral treatment with tenofovir alafenamide (TAF) reduces the risk of liver-related adverse events in patients with non-cirrhotic livers and normal or mildly elevated ALT levels compared with untreated patients.14“
Methods: This retrospective multicenter study included 3734 non-cirrhotic patients (mean age 36.5 yrs) with chronic hepatitis B (CHB) with ALT <2 × the upper limit of normal (ULN); ALT values used a more stringent definition of normal or mildly elevated ALT, as recommended by the 2025 AASLD guideline. To balance baseline characteristics between treated and untreated patients, inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were applied. Of all patients, 37.8% received nucleos(t)ide analogues (NA) treatment.
Key findings:
After IPTW, treated patients had a significantly lower 5-year cumulative incidence of HCC (0.9% vs 4.4%; P < .001) and cirrhosis (4.0% vs 8.9%; P < .001) than untreated patients
Comparison of cumulative incidence of HCC between treated group and untreated group with IPTWComparison of cumulative incidence of cirrhosis between treated group and untreated group with IPTW
Discussion:
“Our real-world evidence supports the ongoing shift toward a more proactive treatment approach for expanding eligibility to include patients with lower threshold ALT levels (>ULN) and HBV DNA (>2000 IU/mL), as recently recommended by the 2025 European Association for the Study of the Liver (EASL) guidelines and the 2024 World Health Organization (WHO) guidelines.4,6“
My take (borrowed in part from the authors): “NA therapy reduced the risk of HCC and cirrhosis in non-cirrhotic CHB patients with mildly elevated ALT levels (1–2 × ULN). These findings support the expansion of antiviral treatment criteria for the early treatment of these patients.” The benefits of NA therapy, though, may vary significantly in younger patients, especially those in the pediatric age group.
Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.
Methods: This was a prospective, randomized, double-blind, placebo-controlled phase 3 study conducted at 91 centers across the United States. Adults (n=772) with heartburn ≥4 d/wk and without erosive esophagitis were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were rerandomized to vonoprazan 10 or 20 mg, and those already on vonoprazan continued the same dose for an additional 20 weeks.
Key findings:
Median percentages of heartburn-free nights during the 4-week placebo-controlled treatment period were 45.5% for placebo, 70.4% for vonoprazan 10 mg, and 71.0% for vonoprazan 20 mg.
Discussion Points:
“In the few randomized controlled trials available which evaluated the effect of PPIs on nocturnal symptoms, the mean and median rates of heartburn-free nights with different therapies, as well as the placebo response, were similar to what we observed in our study (17–19)…Many of the PPI studies assessing therapies for nocturnal symptoms are limited because of their short follow-up duration, often limited to 2–4 weeks.”
Strengths of study: This was a “large multicenter study, placebo-controlled, with a diverse PPI-experienced patient population who presented with reflux symptoms occurring at baseline on approximately 75% of nights.”
Limitation: “A limitation of our study, and many previous studies of NERD, is the lack of positive pH testing to document acid reflux as the cause of symptoms. hus, some subjects likely had conditions other than reflux (e.g., functional heartburn) as a cause of their symptoms, which may reduce the overall response rates seen with acid suppression.”
“The response rates for nighttime heartburn with vonoprazan were not substantially different between patients who reported previous response to PPIs and those who did not, suggesting that previous PPI response may not be a predictor of response to treatment with vonoprazan. However, this observation was based on a post hoc analysis.”
My take (borrowed from the authors): “Vonoprazan had a rapid effect on nighttime heartburn symptoms which was sustained through 24 weeks.”
DM Cohn et al.N Engl J Med2026;395:1471-1482. Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
Background: “Lonvoguran ziclumeran (lonvo-z) — an investigational, in vivo gene-editing treatment based on clustered regularly interspaced short palindromic repeats (CRISPR) — is being developed as a single-dose treatment for hereditary angioedema”
Methods: 80 patients (16 yrs and older) underwent randomization; 52 were assigned to receive lonvo-z and 28 to receive placebo.
Key findings:
Between weeks 5-28, there were 62% of the lonvo-z group that had no attacks compared to 11% of the placebo group
Safety: “The most common adverse effect (occurring in >10% of the patients in the lonvo-z group) included infusion-related reaction, headache, fatigue, back pain, and upper respiratory tract infection. No serious or grade 3 or higher adverse events were reported in the lonvo-z group”
Discussion points:
“The edit to the gene KLKB1 is intended to be permanent after treatment with lonvo-z.”
Safety: “Consideration must therefore be given to the long-term safety of plasma prekallikrein knockdown. Reports in the literature of a rare congenital plasma kallikrein deficiency (Fletcher factor deficiency) suggest that such persons are healthy and have prolonged activated partial-thromboplastin time without an associated bleeding risk19…The most prevalent cardiovascular condition reported in persons with congenital plasma kallikrein deficiency is hypertension,20,22 which has not been reported as an adverse event in patients treated with lonvo-z to date.”
“Another important consideration is the potential risk of off-target editing…Across all clinical trials conducted with lonvo-z to date, no evidence of adverse effects attributable to off-target editing has been observed.”
My take: This is a remarkable achievement; a single CRISPR infusion may cure individuals with Hereditary Angioedema. Long-term data is needed to more fully understand the safety profile. While this infusion is likely to be quite costly, the currently available treatments are also very expensive and without a defined end-point.